Geistlich Pharma’s three business units (BUs) – Biomaterials, Surgery and Medical – each achieved double-digit growth rates in our reporting currency. The Asia & Pacific and EMEA regions stand out for their continued strong performance, but all the regions worldwide contributed to our growth. Almost without exception, the sales volumes and turnover of BU Biomaterials are heading in the right direction in all countries. Thanks to a very good performance in our markets in Germany and Brazil, BU Surgery ended up exceeding expectations. The same applied to BU Medical, which exceeded an ambitious budget and continues its successful growth.
A commitment to Switzerland
For the 2019 reporting period, it is essential to keep reinforcing our main markets and developing new ones. This year the eleventh Geistlich Pharma affiliate will start operating in Japan, and the final stage of the “888plus” extension at Wolhusen will also be completed in 2019. The extension is a commitment to Switzerland and testifies to Geistlich Pharma’s determination to control all its operations and offer everything from one source. As a pioneer in regenerative dentistry, this has long been the company’s tried and tested strategy.